期刊
CANCERS
卷 15, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/cancers15072036
关键词
inflammatory breast cancer; minimal residual disease; cancer relapse; cancer epigenome; metastasis prevention; intrinsic resistance; cell culture model; cancer quiescence; PD-L1; JQ1
类别
We treated highly metabolically adaptable triple-negative inflammatory breast cancer cells with JQ1 and found that it inhibited therapy-resistant cells. Although JQ1 couldn't kill these resistant cells, it sensitized them to treatment with doxorubicin and paclitaxel. Additionally, JQ1 reduced PD-L1 protein levels, indicating a potential improvement in immunotherapy response.
We treated highly metabolically adaptable (SUM149-MA) triple-negative inflammatory breast cancer cells and their control parental SUM149-Luc cell line with JQ1 for long periods to determine its efficacy at inhibiting therapy-resistant cells. After 20 days of treatment with 1-2 mu M of JQ1, which killed majority of cells in the parental cell line, a large number of SUM149-MA cells survived, consistent with their pan-resistant nature. Interestingly, though, the JQ1 treatment sensitized resistant cancer cells in both the SUM149-MA and SUM149-Luc cell lines to subsequent treatment with doxorubicin and paclitaxel. To measure JQ1-mediated sensitization of resistant cancer cells, we first eradicated approximately 99% of relatively chemotherapy-sensitive cancer cells in culture dishes by long treatments with doxorubicin or paclitaxel, and then analyzed the remaining resistant cells for survival and growth into colonies. In addition, combination, rather than sequential, treatment with JQ1 and doxorubicin was also effective in overcoming resistance. Notably, Western blotting showed that JQ1-treated cancer cells had significantly lower levels of PD-L1 protein than did untreated cells, indicating that JQ1 treatment may reduce tumor-mediated immune suppression and improve the response to immunotherapy targeting PD-L1. Finally, JQ1 treatment with a low 62.5 nM dose sensitized another resistant cell line, FC-IBC02-MA, to treatment with doxorubicin and paclitaxel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据